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Highly active antiretroviral therapy (HAART) has been shown to be effective in different populations, but data
among injection drug users are limited. Human immunodeficiency virus-infected injection drug users recruited into
the Acquired Immunodeficiency Syndrome Link to Intravenous Experiences (ALIVE) Study as early as 1988 were
tested semiannually to identify their first CD4-positive T-lymphocyte cell count below 200/ll; they were followed for
mortality through 2002. Visits were categorized into the pre-HAART (before mid-1996) and the HAART eras and
further categorized by HAART use. Survival analysis with staggered entry was used to evaluate the effect of
HAART on acquired immunodeficiency syndrome-related mortality, adjusting for other medications and demo-
graphic, clinical, and behavioral factors. Among 665 participants, 258 died during 2,402 person-years of follow-up.
Compared with survival in the pre-HAART era, survival in the HAART era was shown by multivariate analysis to be
improved for both those who did and did not receive HAART (relative hazards ¼ 0.06 and 0.33, respectively; p <
0.001). Inferences were unchanged after restricting analyses to data starting with 1993 and considerations of lead-
time bias and human immunodeficiency viral load. The annual CD4-positive T-lymphocyte cell decline was less in
untreated HAART-era participants than in pre-HAART-era participants (10/ll vs. 37/ll, respectively), suggest-
ing that changing indications for treatment may have contributed to improved survival and that analyses restricted
to the HAART era probably underestimate HAART effectiveness.
antiretroviral therapy, highly active; HIV; substance abuse, intravenous; substance-related disorders; survival;
treatment outcome
Abbreviations: AIDS, acquired immunodeficiency syndrome; ALIVE, AIDS Link to Intravenous Experiences; CD4þ, CD4-positive
T lymphocytes; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus.
Highly active antiretroviral therapy (HAART) signifi-
cantly improves the prognosis of human immunodeficiency
virus (HIV)-infected persons by reducing HIV load, increas-
ing cell levels of CD4-positive T lymphocytes (CD4þ), de-
laying progression to acquired immunodeficiency syndrome
(AIDS), and reducing mortality (1–7). Most clinical efficacy
studies have been conducted in predominantly White male
study populations; there are fewer data among minorities
and injection drug users (8, 9). Data from cohort and sur-
veillance studies have suggested less benefit of HAART
among minorities and injection drug users (10, 11). While
earlier studies have shown that lack of or delayed access was
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a major problem in these populations (12, 13), the propor-
tion gaining access has improved over time (14). Also, be-
cause injection drug users have an excess mortality risk over
their population peers related to their drug use (15), the
extent to which HAART improves survival in these popula-
tions is unclear.
Among the predictors of HIV disease progression while
on HAART, the CD4þ cell level is the most important (5–7).
Although current clinical guidelines recommend initiating
HAART when CD4þ cell levels are less than 200/ll, and
possibly when 200–350/ll (16, 17), use of antiretroviral
therapy for those with advanced immunosuppression has
been constant since the introduction of such therapy. We
therefore sought to evaluate survival among persons with
CD4þ cell counts below 200/ll, stratified by the availability
and use of HAART, within a large cohort of HIV-infected,
predominantly African-American injection drug users fol-
lowed for up to 14 years.
MATERIALS AND METHODS
Population
Participants were part of the AIDS Link to Intravenous
Experiences (ALIVE) Study in Baltimore, Maryland, al-
ready described in detail elsewhere (18). The study recruited
injection drug users through community outreach starting in
1988–1989, with additional recruitments in 1994 and 1998.
Semiannual follow-up visits included comprehensive inter-
views (sexual behavior, drug use, andmedical history includ-
ing HAART use during the preceding 6 months), a clinical
examination, and phlebotomy. The current study included
665 participants who were HIV seropositive and had at least
one visit with a CD4þ cell count below 200 cells/ll. Follow-
up for this analysis started with the date of the index visit,
when the CD4þ cell count for each participant first dropped
below 200/ll, and continued through December 31, 2002.
This censoring date was determined on the basis of the last
update (in 2004) of death information obtained through the
National Death Index to permit lags in reporting.
Ascertainment of death and cause of death
Study staff were notified of deaths during routine follow-
up contact with family members or partners of participants
with missed visits. Death certificates were obtained from the
Maryland State Vital Records Office for confirmation. For
all participants including those lost to follow-up, records
were requested from the National Death Index Plus. Confir-
mation of correct matches was done with the requested
death certificates, medical examiner reports, and medical
record review.
Cause of death was categorized (19) as HIV related if the
participant was HIV infected and if the primary cause of
death was AIDS/HIV or included an AIDS-defining oppor-
tunistic infection using the 1993 Centers for Disease Control
and Prevention definition (20). Otherwise, death was cate-
gorized as non-AIDS related. Cause of death was classified
as unknown if there was no death certificate available, or if
the cause of death was not provided.
Definition of HAART groups
All observations prior to June 30, 1996, were considered
pre-HAART; observations after that date were considered as
being in the HAART era. Persons in the pre-HAART era
could have received mono- or dual nucleoside antiretroviral
therapy, anti-opportunistic infection medications, or no anti-
retroviral treatment. In the HAART era, we also distin-
guished between individuals who reported using HAART
(coded as ‘‘treatment’’ group) and the others (coded as
‘‘no HAART treatment’’) who reported receiving other anti-
retroviral or anti-opportunistic infection medications or no
antiretroviral treatment (‘‘no treatment’’). The definition of
HAART was based on the International AIDS Society–US
panel and the US Public Health Service guidelines relevant
to the study period (16, 17). Therapy use was updated at
each follow-up visit and based on self-reports.
Laboratory assays
HIV antibodies were assayed using commercial tests in-
terpreted with standard criteria. T-cell subsets were deter-
mined by flow cytometry. HIV plasma viral load was
determined using reverse transcriptase polymerase chain re-
action (Amplicor HIV-1 Monitor Test, version 1.5; Roche
Molecular Systems, Inc., Branchburg, New Jersey) on speci-
mens stored at 70C prior to viral load determinations.
Statistical analysis
Mortality rates were calculated using person-time tech-
niques. Kaplan-Meier survival curves and log-rank tests were
used to compare time to death among three groups: pre-
HAARTera, HAARTera-treated, and HAARTera-untreated
drug users. The time origin was defined as the study visit
when CD4þ cell counts first fell below 200/ll (index visit).
Group membership was updated as a time-dependent covar-
iate, but the survival time for each person was evaluated
relative to the origin. Thus, for example, a person could have
an index visit in the pre-HAART era, then move to the
HAART era, and sequentially contribute time to both
groups, with a delayed entry (21, 22). In the HAART era,
a person could switch between the treatment and no treat-
ment groups, depending on the reported anti-HIV medica-
tions received at each visit. As there might be residual
benefit for survival among those not on HAART but who
had prior HAART, analyses were repeated with HAART
defined as a step function, being fixed at 1 following initi-
ation. To examine potential survivor (or frailty) bias, we also
repeated the Kaplan-Meier analyses, restricting the analyses
of mortality to those whose first CD4þ count of less than
200 cells/ll was in or after 1993 instead of 1988.
For theKaplan-Meier analysis, censoring timewas defined
as the earliest date of the following events: 1) if the person
was known to be alive at the end of the study, December 31,
2002; 2) if the personwas lost to follow-up, the date of the last
visit plus 9 months (or interval to the end of the study if
shorter); 3) if the person died of non-AIDS-related causes,
the date of death; and 4) if the person’s death was AIDS
related and the interval between the last visit and death was
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longer than 2 years, the observation was censored at the date
of the last visit plus 2 years. This was necessary, as the rele-
vance of participant data measured more than 2 years before
death with regard to mortality was questionable.
Survival was examined using Cox regression models with
time-dependent covariates. First, univariate associations were
explored, adjusted for ‘‘lead-time bias,’’ using a proxy lead
time variable, defined as the length of time on the study at
the index visit, that is, the time interval (in years) between
the first follow-up visit in the ALIVE Study and the first visit
with a CD4 count of less than 200 cells/ll. From this, mul-
tivariable models were constructed to adjust simultaneously
for potential confounding factors and to formally test for
interactions. These factors included other HIV-related med-
ications, clinical status, sociodemographic characteristics,
alcohol and drug use, insurance status, and hospitalizations.
Evaluation of the significance of associations between the
various factors and survival was based on estimates of ro-
bust variances that accounted for the correlation among ob-
servations from the same participants.
To summarize longitudinal trends in CD4þ cells, in each
of the three groups, we used linear regression with general-
ized estimating equations to adjust for intraperson correla-
tion. Estimates of slopes are given with robust standard
errors and confidence intervals.
RESULTS
From cohort recruitment, therewere 917 HIV-seropositive
participants at baseline, of whom 505 had a visit with
a CD4 T-lymphocyte count of less than 200/ll at least
once during follow-up. There were also 330 HIV sero-
converters, of whom 160 had a visit with a CD4 count
of less than 200/ll at least once during follow-up. Of the
665 total participants with initial CD4þ cell counts of less
than 200/ll at baseline (n ¼ 93) or anytime during
ALIVE Study follow-up (n ¼ 572), the overall demo-
graphics at entry into the study were as follows: median
age, 39.2 years; Black, 94.6 percent; and male, 74.6 per-
cent. In the 6 months before the initial CD4þ cell count
of less than 200/ll, 18.6 percent were homeless, and
63.7 percent injected illicit drugs, of whom 34.1 percent
injected at least daily and 18.2 percent smoked crack or
snorted cocaine.
The 665 participants contributed a total of 2,401.6
person-years of observation, including 977.3 person-years
before and 1,424.4 person-years after the introduction of
HAART. Among those in follow-up after 1996, 62.1 percent
ever received HAART (of whom 48.2 percent were anti-
retroviral naive before HAART). Among the 427 participants
restricted to the HAART era, those who received HAART
(n ¼ 265) contributed 507.8 person-years, and those not on
HAART contributed 916.6 person-years of observation.
Causes of death for the entire study period, by numbers of
participants, included the following: AIDS, 222; infection,
48; drug related/overdose, 39; trauma, 7; cancer (non-AIDS),
11; and systemic, 48. ‘‘Systemic’’ causes included renal
(including end-stage renal disease), pulmonary, cardiac (in-
cluding cardiovascular/neurologic, i.e., stroke), and other
neurologic (including encephalopathy) causes, as well as
gastrointestinal (including pancreatic, liver, diabetes) causes
and chronic alcoholism. For survival analyses, nine AIDS-
related deaths were censored, since their last follow-up visit
was more than 2 years before death (see Materials and
Methods), and thus 213 deaths appear in the analyses.
Causes of death were similar in the pre-HAART and
HAART eras (data not shown).
The all-cause mortality rate in the cohort overall between
study inception in 1988 and 2002 was 15.7/100 person-years
(95 percent confidence interval (CI): 14.1, 17.3). The HIV-
related mortality rate was 8.9/100 person-years (95 percent
CI: 7.7, 10.2). Mortality rates were significantly (p < 0.001)
lower during the HAART era (5.7/100 person-years) than in
the pre-HAART era (15.9/100 person-years), as was the
relative hazard of 0.24 (95 percent CI: 0.18, 0.32).
Figure 1 shows the Kaplan-Meier curves for three groups:
HAART era treated with HAART; HAART era not treated
with HAART; and the pre-HAARTera. Mortality was signif-
icantly (log-rank test: p < 0.001) lower in both the HAART
era-treated group (relative hazard ¼ 0.05, 95 percent CI:
0.02, 0.12) and the HAART era-untreated group (relative
hazard ¼ 0.27, 95 percent CI: 0.19, 0.38) than in the pre-
HAART referent group (table 1). When observations were
restricted to the HAART era, mortality was lower among
those who received treatment than among those who did
not (relative hazard ¼ 0.42, 95 percent CI: 0.24, 0.73).
We considered whether the improved mortality after 1996
might be due to different methodological concerns. When
we repeated the analyses shown in figure 1, restricted to
those whose first CD4þ count of less than 200 cells/ll was
in 1993 or later, the results were unchanged. With pre-
HAART as the referent, relative hazards for the HAART
era treated and the untreated were 0.13 and 0.31, respec-
tively. We also performed stratified analyses to consider the
length of time in the study (‘‘lead time’’) as a covariate; ad-
justment for this did not alter the relations shown in figure 1.
FIGURE 1. Kaplan-Meier curve of survival by availability and uti-
lization of highly active antiretroviral therapy (HAART) among human
immunodeficiency virus (HIV)-seropositive injection drug users,
ALIVE Study, 1988–2002. ALIVE, Acquired Immunodeficiency Syn-
drome Link to Intravenous Experiences.
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We examined the median initial CD4þ cell count by the
intervals used for lead time; no significant differences
were observed (data not shown). We also restricted analysis
to persons among whom we observed the first drop in
CD4þ cell count below 200/ll (i.e., excluding those already
at less than 200/ll at baseline), and the results did not
change (data not shown). Finally, repeating Kaplan-Meier
analyses using HAART as a fixed variable showed results
similar to those using HAART as a time-dependent variable
(data not shown).
Table 2 shows the univariate associations between mor-
tality and select sociodemographic factors by HAART sta-
tus, as well as participant numbers per group (allowing for
crossover to other groups), person-years, and mortality rates/
100 person-years. Across each of these sociodemographic
variables, mortality was higher in the pre-HAART than in
the HAART era. Across treatment eras and categories, age,
gender, race, and homelessness in the prior 6 months were
each not significantly associated with mortality.
Across each of the drug use variables presented (table 3),
mortality was lower in the HAART era than in the pre-
HAART era. In univariate analysis, mortality was inversely
associated with the use of alcohol (relative hazard ¼ 0.64),
although this effect was much weaker or reversed in the
HAART era. Snorting cocaine was also associated with
lower mortality (relative hazard ¼ 0.32), a finding that per-
sisted in the HAART era. No differences in mortality were
noted by drug detoxification or any methadone maintenance
(table 2), by injection frequency and type of drug injected
(i.e., heroin, cocaine, or both), or by cigarette smoking (data
not shown).
For most of the clinical factors evaluated (table 4), mor-
tality was lower in the HAART-era than in the pre-HAART-
era groups, although this distinction was less apparent with
lower CD4þ cell counts at study entry and with the diagno-
sis of sepsis. Relative hazards for mortality by the clinical
variables across the periods of observation showed that mor-
tality was associated with a CD4þ cell count of less than
150/ll at entry (relative hazard¼ 2.32) or with other clinical
outcomes, including anemia (relative hazard ¼ 4.36), sepsis
(relative hazard ¼ 3.02), bacterial pneumonia (relative
hazard ¼ 3.03), oral candidiasis or thrush (relative hazard¼
2.60), inpatient visits (relative hazard ¼ 2.79), and out-
patient or emergency room visits (relative hazard ¼ 1.87).
In terms of antiretroviral treatment or use of prophylactic
medicines (table 5), the univariate analysis showed that
mortality was markedly reduced for those receiving
HAART in contrast to those not receiving HAART (relative
hazard ¼ 0.04), but mortality was not significantly lower in
persons who received antiretroviral therapy that did not
meet HAART criteria. The use of other HIV-related medi-
cines against theMycobacterium avium complex and fungal
diseases (predominantly candidiasis) was associated with
higher mortality (relative hazard ¼ 2.26 and 3.18, respec-
tively). Similarly, Pneumocystis carinii pneumonia medica-
tion was associated with higher mortality, unless the person
was also receiving HAART (table 5).
Table 6 shows the results of the final multivariable Cox
model incorporating period (pre-HAARTand HAARTeras),
use of HAART and other medications, and clinical, socio-
demographic, and drug use factors while adjusting for lead
time. Mortality was lower for persons receiving HAARTand
persons in the HAART era who did not receive HAART
(adjusted relative hazard¼ 0.06 and 0.33, respectively) than
in the pre-HAART era. Within the HAART era only, the
adjusted relative hazard for the HAART treated versus those
not treated was 0.16. Of note, after consideration of the time
period and use of HAART, both combination antiretroviral
therapy and monotherapy were modestly protective (relative
hazard ¼ 0.59 and 0.80, respectively). Likewise, after ad-
justment, a modest protective effect of P. carinii prophylaxis
was observed (relative hazard¼ 0.81), but not for other anti-
opportunistic infection medicines. Anemia, thrush, and hos-
pitalization were associated with a higher probability of
death (table 6). Notably, mortality was lower for women than
men (relative hazard ¼ 0.74). Recent injection drug use was
not associated with death, nor was frequency of injection
(data not shown). Snorting cocaine was associated with
lower mortality (relative hazard ¼ 0.27). Formal tests of in-
teraction of inhaled cocaine by use of HAART showed no
significant associations (i.e., separately for snort, sniff, and
smoke and then combined as ‘‘any inhaled’’). Interactions of
HAART and anti-opportunistic infections were not signifi-
cant (data not shown). Analyses repeated using HAART as
a fixed variable showed similar results to those of models
treating HAART as time dependent (data not shown).
In analyses that incorporated HIV load, the sample size
was reduced (n¼ 460); the median viral load was lowest for
the HAART-treated group but was similar for the other two
groups. Adding viral load to the final model showed a pos-
itive association with mortality but no change in survival
estimates for the three treatment groups (data not shown).
TABLE 1. Incidence rate and relative hazards of survival by utilization of HAART*








Pre-HAART 453 977 15.86 1.00 Referent
Post-HAART, untreated 408 917 5.67 0.27 0.19, 0.38
Post-HAART, treated 242 508 1.18 0.05 0.02, 0.12
* HAART, highly active antiretroviral therapy; ALIVE, Acquired Immunodeficiency Syndrome
Link to Intravenous Experiences.
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TABLE 2. Univariate associations of HIV* mortality with sociodemographic factors and












No.§ 24 21 11
Person-years 43 50 24
Rate 18.54 0 4.19 1.00
African American
No. 429 387 231
Person-years 934 867 484
Rate 15.74 6.00 1.03 0.98 0.956
Gender
Male
No. 345 296 176
Person-years 726 664 367
Rate 15.84 6.03 1.36 1.00
Female
No. 108 112 66
Person-years 251 253 141
Rate 15.91 4.74 0.71 0.91 0.543
Age (years)
<30
No. 47 18 3
Person-years 79 27 2
Rate 16.36 0 0 1.00
30–40
No. 259 162 61
Person-years 538 306 89
Rate 14.88 5.88 1.13 0.83 0.558
>40
No. 206 295 201
Person-years 361 583 417
Rate 17.21 5.83 1.20 0.91 0.760
Homeless
No
No. 424 377 233
Person-years 828 773 467
Rate 15.58 5.56 1.07 1.00
Yes
No. 155 121 47
Person-years 149 144 41
Rate 17.41 6.27 2.43 1.28 0.157
* HIV, human immunodeficiency virus; HAART, highly active antiretroviral therapy; ALIVE,
Acquired Immunodeficiency Syndrome Link to Intravenous Experiences.
yRelative hazards are for overall associations, adjusted for lead time (see text).
z ‘‘Treatment’’ and ‘‘no treatment’’ refer to receipt of the HAART regimen (see text).
§ Number of participants in each category for the fixed factors and the number contributing
information to each category of time-dependent factors.
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We next considered whether the improved survival in the
HAARTera might be due to selection into treatment. Assum-
ing that the pre-HAART-era group combines patients who
might ormight not have receivedHAARTif it were available,
that CD4þ cell count is a marker of health, and that sicker
patients would receive HAART, then those not receiving
HAARTafter 1996 should have higherCD4þ cell counts than
those in the pre-HAART group. With longitudinal data anal-
ysis methods, the average annual CD4þ cell declines for the
pre-HAART, HAART-untreated, and HAART-treated groups
were 36.6 (95 percent CI: 42.0, 31.2), 10.1 (95 per-
cent CI: 13.9, 6.3), and 3.7 (95 percent CI: 4.2, 11.5),
respectively. The rates/100 person-years for outpatient/emer-
gency room visits for the three groups were 1.51, 1.24, and
1.67, respectively. Both untreated and treated HAART-era
groups were less likely than the pre-HAART-era group to
be active injectors or homeless, but they were more likely
to be in methadone treatment (data not shown).
DISCUSSION
Because availability and utilization of HAART in pre-
dominantly minority injection drug users have lagged be-
hind those in other populations (14), data have been sparse
on the effectiveness of HAART in this population. Earlier
studies in other populations have focused on either the
survival in periods before versus after the introduction
of HAART or comparisons restricted to the HAART era
between those receiving or not receiving treatment (5–7,
23–25). Our study utilized both approaches, and each dem-
onstrated results similar to those of these previous studies,
suggesting that the benefits reported for HAART extend to
this population.
While the dramatic improvement in survival from the
pre-HAART era to the HAART era suggests a potent effect
of HAART, we also noted a dramatic improvement in
survival between the pre-HAART-era and the HAART-era
TABLE 3. Univariate associations of HIV* mortality with drug use factors and rates/100
person-years by HAART* strata, ALIVE* Study, 1988–2002
Time-dependent factors











No.§ 264 272 181
Person-years 374 435 333
Rate 23.02 5.75 0.60 1.00
Yes
No. 334 271 133
Person-years 604 482 175
Rate 11.43 5.60 2.28 0.64 0.002
Crack (any)
No
No. 424 379 225
Person-years 822 776 453
Rate 17.27 5.28 1.10 1.00
Yes
No. 131 110 51
Person-years 155 141 55
Rate 8.39 7.82 1.82 0.72 0.117
Snort cocaine (any)
No
No. 448 401 240
Person-years 930 881 501
Rate 16.35 5.90 1.20 1.00
Yes
No. 60 44 12
Person-years 48 36 7
Rate 6.29 0 0 0.32 0.039
Table continues
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participants who did not receive potent antiretroviral ther-
apy. This finding suggests that factors other than HAART
therapy itself might influence survival. Such factors might
include lead-time bias, frailty or survival bias, exposure to
other antiretrovirals, and selection for treatment.
A possible consideration for the improved survival among
the post-1996 participants not receiving HAART is lead-
time bias, since the study started with prevalent cases of first
CD4þ cell counts below 200/ll. However, neither excluding
prevalent cases nor controlling for lead time affected the
inferences. Another possible consideration is that persons
with CD4þ cell counts below 200/ll during the earlier part
of the study were more frail than those during the later part
of the study, so that the results might have reflected a survi-
vor bias. When analyses were restricted to those whose first
CD4þ cell count of less than 200 cells/ll was in 1993
(3 years prior to the introduction of HAART) or later, sur-
vival comparisons were unchanged. A related consideration
is that a host genetic variant might be contributing to a sur-
vivor bias. However, a comparison of the established geno-
type frequencies for HIV progression (26–34) by period
revealed no difference in survival for any genotype, arguing
against host genetics as a major factor in the improved sur-
vival of those in the HAART era (data not shown).
We then considered whether utilization of antiretroviral
therapy other than HAART or other HIV medications, such
TABLE 3. Continued
Time-dependent factors











No. 263 254 184
Person-years 379 418 330
Rate 16.63 5.50 1.52 1.00
Yes
No. 342 294 125
Person-years 599 498 178




No. 447 391 218
Person-years 922 792 385
Rate 16.06 5.81 1.30 1.00
Yes
No. 71 110 77
Person-years 55 125 122
Rate 12.62 4.81 0.82 0.80 0.430
Detoxification
No
No. 439 391 234
Person-years 866 828 463
Rate 16.51 5.67 1.08 1.00
Yes
No. 112 99 55
Person-years 111 88 44
Rate 10.80 5.67 2.25 0.74 0.216
* HIV, human immunodeficiency virus; HAART, highly active antiretroviral therapy; ALIVE,
Acquired Immunodeficiency Syndrome Link to Intravenous Experiences.
yRelative hazards are for overall associations, adjusted for lead time (see text).
z ‘‘Treatment’’ and ‘‘no treatment’’ refer to receipt of the HAART regimen (see text).
§ Number of participants in each category for the fixed factors and the number contributing
information to each category of time-dependent factors.
Survival in HIV-infected Drug Users on HAART 1005
Am J Epidemiol 2005;161:999–1012
as anti-P. carinii, anti-M. avium complex, or antifungal med-
ications, might have influenced the observed associations.
We noted that survival among individuals on non-HAART
antiretroviral treatment or on prophylactic medicines im-
proved during the HAART era, suggesting possible changes
in indications or clinical care over time. However, even after
accounting for other antiretroviral treatment or other HIV-
related medicines, in models that also adjusted for CD4þ cell
count and clinical status, we still showed similar associations
of protection using HAARTor being in the HAARTera with
or without treatment.
A separate consideration to tie together the discrepancy in
results is the process of selection into treatment. As earlier
studies during the era of antiretroviral monotherapy suggest,
TABLE 4. Univariate associations of HIV* mortality and health factors and rates/100
person-years by HAART* strata, ALIVE* Study, 1988–2002
Time-dependent factors
during last 6 months
Pre-HAART
era








No.§ 245 251 143
Person-years 555 619 311
Rate 11.17 3.88 0.32 1.00
150
No. 208 157 99
Person-years 422 298 197




No. 422 357 223
Person-years 768 714 427
Rate 9.37 2.24 0.70 1.00
Yes
No. 200 182 80
Person-years 209 203 81
Rate 39.71 17.73 3.71 4.36 <0.001
Sepsis
No
No. 452 407 240
Person-years 961 909 503
Rate 15.40 5.50 1.00 1.00
Yes
No. 26 13 7
Person-years 16 8 4
Rate 43.66 26.10 22.95 3.02 <0.001
Any pneumonia
No
No. 442 392 233
Person-years 856 835 470
Rate 12.27 4.91 0.90 1.00
Yes
No. 159 110 52
Person-years 122 82 37
Rate 41.11 13.48 5.34 3.03 <0.001
Table continues
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sicker patients are more likely to receive therapy (35). The
remarkable effectiveness of HAART (1–5) could clearly pre-
dominate over the fact that sicker individuals receive the
treatment. However, for treatment of modest potency (but
proven in randomized controlled trials) such asmonotherapy,
it is difficult to know how much one factor (treatment asso-
ciated with poorer prognosis) is masking the effect of the
other (i.e., treatment effectiveness). As noted in the Results,
in the pre-HAART era, ‘‘selection for treatment’’ (i.e., for
sicker patients) appears to trump the effectiveness of anti-
retroviral therapy (with mono- more so than dual therapy).
However, in theHAARTera, combination non-HAART ther-
apy is associated with a protective effect. Multiple mecha-
nisms may be at play including increased access (14), which
we accounted for in this study, and evolving readiness for
HIV treatment. Also, in the pre-HAART era, combination
therapy was the best available and used for the sickest pa-
tients. However, in the HAART era, particularly early on
before the ramifications of resistance were fully appreciated,
combination therapy was used as a prelude to HAARTand at
TABLE 4. Continued
Time-dependent factors
during last 6 months
Pre-HAART
era








No. 425 371 223
Person-years 727 774 432
Rate 11.14 4.13 0.70 1.00
Yes
No. 226 150 76
Person-years 250 142 76




No. 420 371 227
Person-years 698 749 427
Rate 10.75 4.28 0.50 1.00
Yes
No. 268 198 97
Person-years 279 168 81





No. 246 220 48
Person-years 252 277 35
Rate 10.31 3.25 0 1.00
Yes
No. 407 363 233
Person-years 690 634 471
Rate 18.27 6.78 1.27 1.87 0.001
* HIV, human immunodeficiency virus; HAART, highly active antiretroviral therapy; ALIVE,
Acquired Immunodeficiency Syndrome Link to Intravenous Experiences.
yRelative hazards are for overall associations, adjusted for lead time (see text).
z ‘‘Treatment’’ and ‘‘no treatment’’ refer to receipt of the HAART regimen (see text).
§ Number of participants in each category for the fixed factors and the number contributing
information to each category of time-dependent factors.
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earlier HIV stages, while HAARTwas reserved for the sick-
est patients. Thus, the improved survival of the HAART-era
group not treated with HAART compared with the pre-
HAART group may reflect evolving considerations for anti-
retroviral therapies. The longitudinal data analysis of CD4þ
cell counts supports this conclusion of treatment selection.
The observation that the CD4þ cell count decreased less in
the HAART-untreated patients than in the pre-HAART-era
patients suggests that this groupwas less ill (given themodest
effectiveness of antiretroviral therapies short of HAART),
TABLE 5. Univariate associations of HIV* mortality and medication use factors and
rates/100 person-years by HAART* strata, ALIVE* Study, 1988–2002
Time-dependent factors
during last 6 months
Pre-HAART
era


















No. 449 374 242
Person-years 933 716 508








No. 402 394 242
Person-years 600 803 508




Rate 18.05 6.16 1.09 0.559
Anti-PCP*
No
No. 422 316 112
Person-years 720 527 140
Rate 13.61 4.18 2.14 1.00
Yes
No. 234 276 205
Person-years 257 390 367
Rate 22.16 7.70 0.82 1.24 0.149
Table continues
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leaving the HAART group as those who had more advanced
disease. However, the increase in CD4þ cell counts among
those receiving HAART indicates the potency of these med-
ications as noted by others. Therefore, with a treatment se-
lection process operating, the effect of treatment in the
HAART era (using the comparison of those in same era but
not receiving HAART) would be underestimated.
Given that the cohort was injection drug users, we con-
sidered the possible effect of illicit drugs on the impact of
HAART on survival. While injection drug use frequency
was not significant, we considered other routes of adminis-
tration. Inhaled cocaine was associated with survival before
1996, but this putative benefit dissipated during the HAART
era. The mechanism underlying these observations is un-
clear. Considering recent data showing that use of metham-
phetamines may have an adverse impact on survival for
those on HAART (36), we find that the absence of an effect
for illicit drugs observed here is not reassuring.
Several study limitations should be acknowledged. The
extent to which this study population represents minority
injection drug users with advanced HIV infection in
Baltimore, Maryland, or in other cities is difficult to
TABLE 5. Continued
Time-dependent factors
during last 6 months
Pre-HAART
era









No. 404 341 180
Person-years 611 653 272
Rate 10.63 4.75 0.73 1.00
Yes
No. 325 253 177
Person-years 366 264 236
Rate 24.60 7.95 1.70 1.90 <0.001
Anti-MAI*
No
No. 452 406 237
Person-years 942 886 480
Rate 14.97 5.53 0.83 1.00
Yes
No. 48 43 40
Person-years 35 31 28
Rate 39.90 9.73 7.23 2.26 <0.001
Antifungal
No
No. 435 383 222
Person-years 793 820 430
Rate 10.35 4.51 0.93 1.00
Yes
No. 188 121 90
Person-years 185 97 77
Rate 39.52 15.54 2.59 3.18 <0.001
* HIV, human immunodeficiency virus; HAART, highly active antiretroviral therapy; ALIVE,
Acquired Immunodeficiency Syndrome Link to Intravenous Experiences; PCP, Pneumocystis
carinii pneumonia; MAI, Mycobacterium avium, M. intracellulare.
yRelative hazards are for overall associations, adjusted for lead time (see text).
z ‘‘Treatment’’ and ‘‘no treatment’’ refer to receipt of the HAART regimen (see text).
§ Number of participants in each category for the fixed factors and the number contributing
information to each category of time-dependent factors.
{ MAI, cytomegalovirus, fungus, tuberculosis.
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determine, although comparisons of our overall study with
samples drawn in other ways in the same city at the same
time (37, 38) are similar. Likewise, our results may differ
from clinic-derived studies because of differences in who
receives no treatment. The results are based on a sample of
injection drug users who had CD4þ cell counts below 200/ll;
this limited inferences to the observed impact of HAARTon
those with advanced immunosuppression. While this was
done to preserve comparability over the length of the study
period, so as to incorporate observations when treatment
was recommended primarily for those with advanced immu-
nosuppression, data from our cohort on thosewith CD4þ cell
counts above 200/ll have been published elsewhere (39).
Another possible limitation involves the use of self-reports
and the concern over responding in a socially desirable
manner. In the absence of reward or sanctions for re-
sponses, most studies have shown that self reports from drug
users are reliable and valid (40). Future studies will need to
more closely examine the possible interactions with
HAART and illicit drugs or treatments for drug abuse, in
terms of pharmacologic effects as well as frequency and
types of toxicities that might affect clinical outcomes in-
cluding survival. While adherence to medications is a con-
sideration for response to medications, measures were not
used until late in the study; assuming that adherence was
imperfect, the results observed likely represent a conserva-
tive estimate of survival, a fact that should not be minimized
in considerations of antiretroviral use in international
settings. Finally, while comparisons of ‘‘before and after’’
studies or historical cohort studies and those involving non-
randomized treatment designs each have well known biases,
we have adjusted for several known biases in this analysis to
limit their impact on the results. In addition, a randomized
controlled clinical trial, which would have fewer biases, is
unlikely to be completed in the near future. This highlights
the importance of carefully conducted and analyzed cohort
studies.
In conclusion, clinicians have been somewhat reluctant to
provide treatment to this population because of concerns
about adherence and evolution of resistance that might be
transmitted to others. While this analysis cannot directly
address these important concerns, the data on improved sur-
vival for those who received therapy suggest that treatment
can work in this and other populations internationally where
reduced access has occurred from reluctance to provide
treatment over concerns of adherence and resistance. Ap-
proaches are needed to reach the intravenous drug-using
population and then to offer and monitor effective antiretro-
viral treatment.
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Not treatedz 0.33 0.22, 0.49
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